Redirection of the reaction between activated protein C and a serpin to the substrate pathway

Thrombosis Research

Volumn 122, Issue 3, 2008, Pages 397-404

  Komissarov, Andrey A ^a   Andreasen, Peter A ^b   Declerck, Paul J ^c   Kamikubo, Yuichi ^d   Zhou, Aiwu ^e   Gruber, András ^f  

^a PORTLAND STATE UNIVERSITY   (United States)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f Oregon Health and Science University Department of Biomedical Engineering   (United States)

Author keywords

Activated protein C; Disseminated intravascular coagulation; Monoclonal antibodies; Plasminogen activator inhibitor 1; Sepsis; Vitronectin

Indexed keywords

MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; SERINE PROTEINASE INHIBITOR; VITRONECTIN;

ALPHA HELIX; ARTICLE; CATALYSIS; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; ENZYME MECHANISM; FLUORESCENCE SPECTROSCOPY; HUMAN; KINETICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SEPSIS; STOICHIOMETRY;

ANTIBODIES, MONOCLONAL; DISSEMINATED INTRAVASCULAR COAGULATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; LIGANDS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BINDING; PROTEIN C; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; SEPSIS; SPECTROMETRY, FLUORESCENCE;

EID: 45849148895     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.10.012     Document Type: Article

References (56)

1. Esmon C.T. Crosstalk between inflammation and thrombosis. Maturitas 47 4 (2004) 305-314
2. Esmon C.T. Protein C pathway in sepsis. Ann Med 34 7-8 (2002) 598-605
3. Castellino F.J. Gene targeting in hemostasis: protein C. Front Biosci 6 (2001) D807-D819
4. Kinasewitz G.T., Yan S.B., Basson B., Comp P., Russell J.A., Cariou A., et al. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care 8 2 (2004) R82-R90
5. Bernard G.R., Ely E.W., Wright T.J., Fraiz J., Stasek Jr. J.E., Russell J.A., et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29 11 (2001) 2051-2059
6. Bernard G.R., Vincent J.L., Laterre P.F., Larosa S.P., Dhainaut J.F., Lopez-Rodriguez A., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 10 (Mar 8 2001) 699-709
7. Heeb M.J., Gruber A., and Griffin J.H. Identification of divalent metal ion-dependent inhibition of activated protein C by alpha 2-macroglobulin and alpha 2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin, and plasmin. J Biol Chem 266 26 (1991) 17606-17612
8. Heeb M.J., Espana F., and Griffin J.H. Inhibition and complexation of activated protein C by two major inhibitors in plasma. Blood 73 2 (1989) 446-454
9. Aird W.C. Natural anticoagulant inhibitors: activated protein C. Best Pract Res Clin Haematol 17 1 (2004) 161-182
10. Okajima K., Koga S., Kaji M., Inoue M., Nakagaki T., Funatsu A., et al. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb Haemost 63 1 (1990) 48-53
11. Silverman G.A., Bird P.I., Carrell R.W., Church F.C., Coughlin P.B., Gettins P.G., et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 276 36 (2001) 33293-33296
12. Suzuki K., Nishioka J., and Hashimoto S. Protein C inhibitor. Purification from human plasma and characterization. J Biol Chem 258 1 (1983) 163-168
13. Heeb M.J., Bischoff R., Courtney M., and Griffin J.H. Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine 358. J Biol Chem 265 4 (1990) 2365-2369
14. Berg D.T., Gerlitz B., Shang J., Smith T., Santa P., Richardson M.A., et al. Engineering the proteolytic specificity of activated protein C improves its pharmacological properties. Proc Natl Acad Sci U S A 100 8 (2003) 4423-4428
15. Stratikos E., and Gettins P.G. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 A and full insertion of the reactive center loop into beta-sheet A. Proc Natl Acad Sci U S A 96 9 (1999) 4808-4813
16. Peterson F.C., and Gettins P.G. Insight into the mechanism of serpin-proteinase inhibition from 2D [1H-15N] NMR studies of the 69 kDa alpha 1-proteinase inhibitor Pittsburgh-trypsin covalent complex. Biochemistry 40 21 (2001) 6284-6292
17. Huntington J.A., Read R.J., and Carrell R.W. Structure of a serpin-protease complex shows inhibition by deformation. Nature 407 6806 (2000) 923-926
18. Rezaie A.R. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 276 19 (2001) 15567-15570
19. Zeerleder S., Schroeder V., Hack C.E., Kohler H.P., and Wuillemin W.A. TAFI and PAI-1 levels in human sepsis. Thromb Res 118 2 (2006) 205-212
20. Watanabe R., Wada H., Miura Y., Murata Y., Watanabe Y., Sakakura M., et al. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura. Clin Appl Thromb Hemost 7 3 (2001) 229-233
21. Iba T., Kidokoro A., Fukunaga M., Sugiyama K., Sawada T., and Kato H. Association between the severity of sepsis and the changes in hemostatic molecular markers and vascular endothelial damage markers. Shock 23 1 (2005) 25-29
22. Gando S., Nakanishi Y., and Tedo I. Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome. Crit Care Med 23 11 (1995) 1835-1842
23. Mesters R.M., Florke N., Ostermann H., and Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 75 6 (1996) 902-907
24. Raaphorst J., Johan Groeneveld A.B., Bossink A.W., and Erik H.C. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost 86 2 (2001) 543-549
25. Hack C.E. Fibrinolysis in disseminated intravascular coagulation. Semin Thromb Hemost 27 6 (2001) 633-638
26. Pralong G., Calandra T., Glauser M.P., Schellekens J., Verhoef J., Bachmann F., et al. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost 61 3 (1989) 459-462
27. Haj M.A., Robbie L.A., Croll A., Adey G.D., and Bennett B. Fibrinolytic changes in a patient with toxic shock syndrome; release of active u-PA. Intensive Care Med 24 3 (1998) 258-261
28. Keyt B.A., Paoni N.F., Refino C.J., Berleau L., Nguyen H., Chow A., et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A 91 9 (1994) 3670-3674
29. Modi N.B., Eppler S., Breed J., Cannon C.P., Braunwald E., and Love T.W. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb Haemost 79 1 (1998) 134-139
30. Komissarov A.A., Declerck P.J., and Shore J.D. Mechanisms of conversion of plasminogen activator inhibitor 1 from a suicide inhibitor to a substrate by monoclonal antibodies. J Biol Chem 277 46 (2002) 43858-43865
31. Komissarov A.A., Declerck P.J., and Shore J.D. Protonation state of a single histidine residue contributes significantly to the kinetics of the reaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator. J Biol Chem 279 22 (2004) 23007-23013
32. Komissarov A.A., Andreasen P.A., Bodker J.S., Declerck P.J., Anagli J.Y., and Shore J.D. Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases. J Biol Chem 280 2 (2005) 1482-1489
33. Komissarov A.A., Zhou A.W., and Declerck P.J. Modulation of serpin reaction through stabilization of transient intermediate by ligands bound to alpha-helix. F. J Biol Chem 282 36 (2007) 26306-26315
34. Shore J.D., Day D.E., Francis-Chmura A.M., Verhamme I., Kvassman J., Lawrence D.A., et al. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J Biol Chem 270 10 (1995) 5395-5398
35. Zhou A., Huntington J.A., Pannu N.S., Carrell R.W., and Read R.J. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 10 7 (2003) 541-544
36. Kamikubo Y., Okumura Y., and Loskutoff D.J. Identification of the disulfide bonds in the recombinant somatomedin B domain of human vitronectin. J Biol Chem 277 30 (2002) 27109-27119
37. Debrock S., and Declerck P.J. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Biochim Biophys Acta 1337 2 (1997) 257-266
38. Nielsen L.S., Andreasen P.A., Grondahl-Hansen J., Huang J.Y., Kristensen P., and Dano K. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells-inhibitor neutralization and one-step affinity purification. Thromb Haemost 55 2 (1986) 206-212
39. Verbeke K., Gils A., and Declerck P.J. Cloning and paratope analysis of an antibody fragment, a rational approach for the design of a PAI-1 inhibitor. J Thromb Haemost 2 2 (2004) 289-297
40. Kvassman J.O., Verhamme I., and Shore J.D. Inhibitory mechanism of serpins: loop insertion forces acylation of plasminogen activator by plasminogen activator inhibitor-1. Biochemistry 37 44 (1998) 15491-15502
41. Bijnens A.P., Gils A., Stassen J.M., Komissarov A.A., Knockaert I., Brouwers E., et al. The distal hinge of the reactive site loop and its proximity: a target to modulate plasminogen activator inhibitor-1 activity. J Biol Chem 276 48 (2001) 44912-44918
42. Tomasini B.R., and Mosher D.F. Vitronectin. Prog Hemostasis Thromb 10 (1991) 269-305
43. Preissner K.T., and Seiffert D. Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb Res 89 1 (1998) 1-21
44. Wiman B., Almquist A., Sigurdardottir O., and Lindahl T. Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma. FEBS Lett 242 1 (1988) 125-128
45. Declerck P.J., De Mol M., Alessi M.C., Baudner S., Paques E.P., Preissner K.T., et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 263 30 (1988) 15454-15461
46. Bijnens A.P., Gils A., Knockaert I., Stassen J.M., and Declerck P.J. Importance of the Hinge Region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies. J Biol Chem 275 9 (2000) 6375-6380
47. Wind T., Jensen M.A., and Andreasen P.A. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding. Eur J Biochem 268 4 (2001) 1095-1106
48. Schousboe S.L., Egelund R., Kirkegaard T., Preissner K.T., Rodenburg K.W., and Andreasen P.A. Vitronectin and substitution of a beta-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against alpha-helix F. Thromb Haemost 83 5 (2000) 742-751
49. Li X., Zou G., Yuan W., and Lu W. Defining the native disulfide topology in the somatomedin B domain of human vitronectin. J Biol Chem 282 8 (2007) 5318-5326
50. Jensen J.K., Durand M.K., Skeldal S., Dupont D.M., Bodker J.S., Wind T., et al. Construction of a plasminogen activator inhibitor-1 variant without measurable affinity to vitronectin but otherwise normal. FEBS Lett 556 1-3 (2004) 175-179
51. Stockmann A., Hess S., Declerck P., Timpl R., and Preissner K.T. Multimeric vitronectin. Identification and characterization of conformation-dependent self-association of the adhesive protein. J Biol Chem 268 30 (1993) 22874-22882
52. Seiffert D., and Loskutoff D.J. Type 1 plasminogen activator inhibitor induces multimerization of plasma vitronectin. A suggested mechanism for the generation of the tissue form of vitronectin in vivo. J Biol Chem 271 47 (1996) 29644-29651
53. Minor K.H., and Peterson C.B. Plasminogen activator inhibitor type 1 promotes the self-association of vitronectin into complexes exhibiting altered incorporation into the extracellular matrix. J Biol Chem 277 12 (2002) 10337-10345
54. Olson S.T., Swanson R., Day D., Verhamme I., Kvassman J., and Shore J.D. Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin. Biochemistry 40 39 (2001) 11742-11756
55. Ibarra C.A., Blouse G.E., Christian T.D., and Shore J.D. The contribution of the exosite residues of plasminogen activator inhibitor-1 to proteinase inhibition. J Biol Chem 279 5 (2004) 3643-3650
56. Sakata Y., Murakami T., Noro A., Mori K., and Matsuda M. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 77 9 (1991) 1949-1957